Plant-Based Vaccines Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

Viral vaccines accounted for 55.63% of revenue in 2025, confirming their position as the cornerstone of the plant-based vaccines market. The segment’s leadership rests on the success of virus-like particle designs that can be updated within days of a new genomic sequence, as Medicago’s former COVID-19 program illustrated before its 2024 closure. As a result, viral candidates continue to capture procurement contracts tied to national stockpile mandates. In contrast, bacterial vaccines are the smallest slice of the current plant-based vaccines market size, but they register the fastest expansion at a 11.83% CAGR thanks to global pressure to combat antimicrobial resistance. Developers leverage plant platforms to present multiple conserved bacterial antigens in a single dose, a feature that aligns with WHO’s 2030 AMR roadmap. The heightened pace of bacterial pipeline additions indicates that the plant-based vaccines market can broaden beyond pandemic-response niches and into routine immunization schedules by decade’s end.

Pipeline depth underscores the divergence. More than 40% of active INDs in 2025 target viral pathogens such as H5N1 and Lassa fever, whereas bacterial projects number fewer than 20 yet enjoy accelerated review under NIAID’s 2026 omnibus funding call. Because many bacterial diseases lack commercial incentives, sponsors expect advanced purchase agreements and BARDA contracts to underpin returns. The net effect is that the plant-based vaccines market share of viral products should retain an absolute majority through 2030, albeit with modest dilution as bacterial assets reach late-stage trials. Strategic differentiation will hinge on cross-protective efficacy data and cost-of-goods metrics that remain favorable for plants versus recombinant protein or conjugate vaccine alternatives.

Tobacco systems delivered 61.88% of 2025 revenue, benefitting from three decades of molecular-farming know-how and a mature supply chain for Nicotiana seedlings. The platform excels at transient expression, permitting developers to scale from lab to 3 million clinical doses in roughly eight weeks—a throughput no other current plant species matches. This speed anchors tobacco’s dominant plant-based vaccines market share; however, regulators are heightening scrutiny of alkaloid carryover and allergen signatures, prompting some firms to hedge with alternative crops. Potato-derived platforms, though only a fraction of the current plant-based vaccines market size, are expanding at 11.95% CAGR. Potatoes appeal because they are globally cultivated food staples with clear allergen-profiling precedents, reducing perceived consumer risk. Companies exploiting this crop also benefit from processing infrastructure already optimized for starch extraction, which can be repurposed for protein capture at minimal incremental capex.

Diversification continues as spinach and lettuce demonstrate transformation yields competitive with tobacco, and Chlorella microalgae gain traction for fully enclosed photobioreactor production that bypasses field-crop regulations. Early adopters position these “other plants” as a hedge against potential regulatory restrictions on genetically engineered tobacco cultivation. If allergen concerns further tighten, potatoes may become the preferred frontline platform, yet most analysts expect tobacco to remain the workhorse of the plant-based vaccines market through at least 2028 because of entrenched expertise and validated master-seed banks.

Human infectious-disease indications contributed 48.10% of 2025 revenue, reflecting COVID-19 aftermath funding and mandatory national influenza stockpile refreshes. The segment gains additional momentum from government calls for universal coronavirus or pan-influenza candidates that can eliminate annual strain matching, a task well suited to plant platforms that allow high-throughput antigen variant screening. Oncology programs, although representing a smaller slice of the plant-based vaccines market size today, are registering a 12.08% CAGR as mRNA-encoded neoantigen strategies transition into tumor-specific virus-like particles produced in plants. Early-phase trials are reporting durable cytotoxic T-cell responses in melanoma and pancreatic cancer cohorts, outcomes that could allow plant-derived approaches to compete with individualized cell therapies at a fraction of the cost.

Veterinary applications remain a steady niche, attracting sponsors that value plants’ ability to sidestep religious or cultural objections associated with porcine or bovine cell-line inputs. The European Medicines Agency’s 2024 guideline on plasmid DNA vaccines has clarified animal-health regulatory pathways, and PlantForm Corporation’s licensing deal for Classical Swine Fever vaccines across the Americas illustrates how veterinary lines can commercialize faster than human counterparts. Over the forecast window, oncology’s share of the plant-based vaccines market is projected to rise, yet infectious-disease revenues should still exceed 40% because of periodic pandemic preparedness surges.

North America retained 44.55% of global revenue in 2025, underpinned by deep NIH grant allocations, a dense network of cGMP suites, and a favorable venture-capital ecosystem. Yet growth is moderating to high single digits as developers digest new FDA mandates for placebo-controlled trials across all platforms, a policy that lengthens pivotal study timelines and raises budget forecasts. The region also confronts post-Medicago investor skepticism, though British American Tobacco’s KBio and Kentucky BioProcessing continue to push Nicotiana-based COVID-19 boosters through Phase II and prepare commercial launch plans. The plant-based vaccines market nevertheless benefits from bipartisan Congressional backing for next-generation biothreat countermeasures, ensuring stable procurement demand.

Asia-Pacific is the fastest-growing cluster, posting a 12.11% CAGR through 2031 as China, India and South Korea expand sovereign biomanufacturing capacity. The Serum Institute of India’s memorandum with CEPI to adopt plant systems for low-cost vaccine output illustrates how local champions can combine price advantages with large, ready domestic markets. China already hosts 89 registries for plant-related cancer vaccine trials, second only to the United States, a sign that regional R&D hubs are maturing quickly. Governments in Japan and Australia are also offering tax credits for molecular-farming investments, which is enticing multinationals to establish satellite facilities rather than export bulk drug substance from North America.

Europe offers sizable addressable volume but is complicated by the 2025 New Genomic Techniques regulation that splits genetically modified plants into two categories. While the European Commission’s biotech strategy signals political will to foster innovation, divergent national implementations can impose staggered approval timelines. Mitsubishi Tanabe Pharma’s tobacco-based influenza candidate advancing through EU Phase III demonstrates that commercial success is possible, yet companies must budget for parallel regulatory submissions to multiple competent authorities. Latin America and the Middle East & Africa remain emerging plays; however, licensing agreements such as PlantForm-POSCO’s veterinary deal in Brazil and CEPI’s Rwanda mRNA project suggest these regions could leapfrog directly to advanced platforms, integrating plant lines alongside mRNA hubs.